Profitable and debt-free CPH knows that it's dirt cheap because it currently trades
less than 2 times its 2020 EBITDA. As such, it just announced that it bought back 205,000 shares in Q4 2020, facts below:
"Update on normal course issuer bid ("NCIB") program: During the quarter ended December 31, 2020 Cipher purchased for cancellation 205,500 common shares under the NCIB program."
https://cipher.investorroom.com/2021-02-10-Cipher-Pharmaceuticals-Enters-into-Co-Promotion-Agreement-with-Verity-Pharmaceuticals-Inc
Reminder. CPH bought back another 30,000 shares in Q3 2020 at
C$1.14, facts below:
"During the period ended September 30, 2020, the Company purchased for cancellation 30,000 common shares at an average price of CAD$1.14 per common share."